Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial

What is it about?

Abatacept prevents the activation of T cells from the immune system and successfully reduces cell damage in patients with several autoimmune conditions. We studied whether abatacept would delay the development of type 1 diabetes. In individuals with positive type 1 diabetes autoantibodies, the drug had all the immune responses we expected, increased insulin secretion, and transiently slowed the development of abnormal glucose in people whose immune system was targeting their insulin producing cells, but the effect was not as long lasting as we expected. Improvements in risk reduction reversed after treatment ended. Abatacept is likely to find a role in modifying the progression of type 1 diabetes.

Featured Image